Drug details
Fulphila (pegfilgrastim-jmdb injection, for subcutaneous use)
type of Hematopoietic Growth Factors
Fulphila (pegfilgrastim-jmdb) is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
This drug may have the following side effects:
- include bone pain and
- pain in the extremities
The following drugs are related to Fulphila, either as a replacement or used together:
- Ziextenzo (pegfilgrastim-bmez injection)